香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 China Tourism Group Duty Free Corporation Limited 中國旅遊集團中免股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：1880） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中國旅遊集團中免股份有限公司在上海證券交易所網站刊登的《中國旅遊 集團中免股份有限公司2025年度審計報告》《中國旅遊集團中免股份有限公司2025 年度內部控制審計報告》《關於中國旅遊集團中免股份有限公司2025年度非經營性 資金佔用及其他關聯資金往來情況匯總表的專項審計報告》《關於中國旅遊集團中 免股份有限公司2025年度涉及財務公司關聯交易的存款、貸款等金融業務匯總表 的專項說明》，僅供參閱。 特此公告。 承董事會命 中國旅遊集團中免股份有限公司 董事會主席 范雲軍先生 中國•北京 2026年3月30日 於本公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 CNGR Advanced Material Co., Ltd. 中偉新材料股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2579） 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條 而 作 出。 茲載列中偉新材料股份有限公司（「本公司」）在深圳證券交易所網站刊登的《2025 年 財 務 報 告》、《2025年 度 內 部 控 制 審 計 報 告》、《2025年 年 度 審 計 報 告》，僅 供 參 閱。 特 此 公 告。 承董事會命 中偉新材料股份有限公司 董 事 長、執 行 董 事 兼 總 裁 鄧偉明先生 香 港，2026年3月30日 於 本 公 告 日 期，本 公 司 董 事 為：(i)執 行 董 事 鄧 偉 明 先 生、鄧 競 先 生、陶 吳 先 生、 廖 恆 ...

Group 1 - The company, Chengzhi Co., stated that it conducts annual impairment tests on goodwill in accordance with the "Enterprise Accounting Standards" and other relevant regulations [2] - The results of the impairment tests determine whether the company needs to recognize goodwill impairment provisions [2]

Core Viewpoint - Tianji Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure regulations, but the company asserts that its production and operational activities remain normal and unaffected by the investigation [2][4]. Group 1: Regulatory Actions - The CSRC has decided to initiate a case against Tianji Co., Ltd. due to issues related to improper goodwill impairment testing, inaccurate financial accounting, and non-compliance with information disclosure regulations [2][4]. - The Guangdong Regulatory Bureau issued an administrative regulatory decision, citing the company's failure to adhere to the "Management Measures for Information Disclosure of Listed Companies" [5]. - The Shenzhen Stock Exchange has also issued a regulatory letter to Tianji Co., Ltd. regarding the same violations [5]. Group 2: Company Response - Tianji Co., Ltd. has expressed its commitment to cooperate with the CSRC and to rectify the identified issues by implementing corrective measures and submitting a written report to the regulatory authorities [6]. - The company plans to enhance its understanding of relevant laws and regulations, improve its internal control systems, and elevate the quality of its information disclosure to protect the interests of shareholders [6]. Group 3: Financial and Shareholder Information - As of February 11, the stock price of Tianji Co., Ltd. was reported at 43.96 yuan per share, with a total market capitalization of 22 billion yuan [7]. - As of January 30, the company had over 180,000 shareholders, reflecting a 2.02% increase in the number of shareholders compared to the previous period [9][10].

Core Viewpoint - Tianji Co., Ltd. is currently under investigation by the China Securities Regulatory Commission (CSRC) for issues related to goodwill impairment testing, inaccurate financial accounting, and non-compliance with information disclosure regulations. The company asserts that these matters will not significantly impact its normal production and operational activities [2][3]. Group 1: Regulatory Actions - On January 15, Tianji Co., Ltd. received an administrative regulatory decision from the Guangdong Regulatory Bureau of the CSRC, citing non-compliance in goodwill impairment testing, financial accounting inaccuracies, and improper information disclosure [2]. - The CSRC has mandated corrective administrative measures for Tianji Co., Ltd. and issued warning letters to key executives, including Chairman Wu Xidun, CFO Yang Zhixuan, and Board Secretary Zheng Wenlong, for their failure to fulfill their duties [2][3]. - The Shenzhen Stock Exchange has also issued a regulatory letter to Tianji Co., Ltd., highlighting similar violations, including improper goodwill impairment testing and failure to appropriately account for employee compensation [3]. Group 2: Company Response - Tianji Co., Ltd. has expressed its commitment to addressing the issues raised in the regulatory documents by conducting self-examinations, formulating corrective measures, and submitting written reports to regulatory authorities [3]. - The company emphasizes the importance of learning from these experiences to enhance compliance awareness, improve internal control systems, and elevate the quality of information disclosure [3]. Group 3: Company Overview - Tianji Co., Ltd. primarily produces lithium hexafluorophosphate and related fluorochemical products, sodium phosphinate and related phosphochemical products, as well as small household appliances [4]. - As of February 11, the stock price of Tianji Co., Ltd. was reported at 43.96 yuan per share, with a total market capitalization of 22 billion yuan [5]. - As of January 30, the company had over 180,000 shareholders, reflecting a recent increase in shareholder numbers [6][7].

Core Viewpoint - The company emphasizes its commitment to integrity in operations and diligent fulfillment of responsibilities, adhering to relevant accounting standards for annual goodwill impairment testing and accounting treatment of inventory and receivables [2] Group 1 - The company conducts annual goodwill impairment tests in accordance with the relevant requirements of the Accounting Standards for Enterprises [2] - Inventory and receivables are accounted for based on aging, ensuring accurate financial reporting [2] - Legal matters are handled according to the rulings, reflecting the company's adherence to regulatory compliance [2] Group 2 - The company strictly follows relevant regulations and its own Information Disclosure Management Measures to fulfill disclosure obligations [2]

Group 1 - The core viewpoint of the article is that the company, Guoyao Yici, has acknowledged a significant funding requirement in its pharmaceutical distribution segment, which has led to an increase in accounts receivable due to external environmental impacts [1] - The company's goodwill is primarily associated with its pharmaceutical retail segment, and it conducts annual impairment tests on asset groups that include goodwill, in accordance with accounting standards and company policies [1] - The results of the impairment tests determine whether the company needs to recognize any impairment losses, thereby accurately reflecting the value of goodwill assets [1]

Group 1 - The company, China National Pharmaceutical Group Corporation (国药一致), stated that it conducts annual impairment tests on asset groups containing goodwill according to accounting standards and company policies [1] - The impairment test results determine whether the company needs to recognize impairment losses, accurately reflecting the value of goodwill assets [1]

Core Viewpoint - Tianwei Food (603317) confirmed that it conducts annual impairment tests on goodwill arising from business combinations, regardless of whether there are indications of impairment, in accordance with the relevant accounting standards [1] Group 1: Goodwill Management - The company adheres to the provisions of the Accounting Standards for Business Enterprises No. 8 regarding goodwill impairment testing [1] - Tianwei Food has not experienced any goodwill impairment in the most recent audited financial year [1] - The company is currently progressing with the goodwill impairment testing for the year 2025 and will disclose any impairment indications in compliance with regulatory requirements [1]

Group 1 - The core point of the article is that Huabao Co., Ltd. has confirmed its goodwill book value as of September 30, 2025, to be 718 million yuan [2] - The company will conduct a goodwill impairment test at the end of the year in accordance with accounting standards, and the results will determine whether to recognize impairment and the amount [2] - Huabao Co., Ltd. emphasizes its commitment to compliance and ensuring that information disclosure is truthful, accurate, and complete, with detailed financial data and impairment situations to be disclosed in the 2025 annual report [2]